ITGA3 and B-cell non-Hodgkin lymphoma: Contrary to T cells, B cells, and B cell lymphomas expressed CD151 with a free ITGA3 binding domain, and targeting integrin-free CD151 in DLBCL may represent a new target for immunotherapy.